Core Viewpoint - The company is closely monitoring market conditions and policy changes, ensuring that its operations remain normal and orderly without being affected by tariffs [1] Company Operations - The company confirmed that all aspects of its production and operations are currently running smoothly and are not impacted by tariff changes [1]

Group 1 - On September 25, Dajia Weikang's stock price fell by 1.40%, with a trading volume of 29.55 million yuan [1] - The financing data on the same day showed a financing buy-in of 1.99 million yuan and a financing repayment of 4.18 million yuan, resulting in a net financing buy of -2.18 million yuan [1] - As of September 25, the total balance of margin trading for Dajia Weikang was 81.06 million yuan, which accounts for 3.50% of its market capitalization [1] Group 2 - As of September 19, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.90% from the previous period [2] - The average circulating shares per person increased by 2.99% to 8,629 shares [2] - For the first half of 2025, Dajia Weikang reported operating revenue of 2.708 billion yuan, a year-on-year increase of 4.16%, while the net profit attributable to the parent company was 893,500 yuan, a significant decrease of 97.19% [2] Group 3 - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included Nu'an Multi-Strategy Mixed A (320016), which held 939,800 shares as a new shareholder [3]

Group 1: Financial Performance - The company achieved a revenue of 270,833.74 million CNY in the first half of 2025, representing a 4.16% increase compared to the same period last year [1] - The net profit attributable to shareholders was 893,533.16 CNY, showing a decline compared to the previous year [1] Group 2: Strategic Focus - The company is transitioning from traditional business growth models to a focus on innovation, high-quality, and diversified operations [1] - Emphasis on developing products and technologies in the field of regenerative medicine to enhance research innovation and clinical transformation [2] Group 3: Cost Management and Profitability - The company aims to strengthen cost control to reduce expenses in production, operations, and management, thereby improving profit margins [2] - The goal is to stabilize company performance and enhance profitability [2] Group 4: Investment Value and Market Position - The company is committed to solidifying its core competitiveness and profitability through talent development and leveraging existing business [2] - The company is poised to capitalize on opportunities in the healthcare industry to enhance its market position and service quality [2] Group 5: Regulatory Environment - Recent government policies promoting consumption and easing market access for high-end medical services are seen as positive signals for the company [2] - The company will closely monitor market demand and actively apply for relevant licenses in response to the new policy environment [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-062 湖南达嘉维康医药产业股份有限公司 关于对外担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）为满足公司全资 子公司及控股子公司日常生产经营和业务发展资金需要，保证公司业务顺利开展， 公司于 2025 年 4 月 17 日、2025 年 5 月 12 日分别召开的第四届董事会第十四次会 议及 2024 年年度股东大会审议通过《关于 2025 年度担保额度预计的议案》，同意 公司 2025 年度为公司全资子公司及控股子公司提供担保，担保额度预计不超过 30 亿 元。具体内容详见公司于 2025 年 4 月 21 日在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于 2025 年度担保额度预计的公告》（公告编号：2025-026）。 二、对外担保进展情况 近日，公司与中国民生银行股份有限公司长沙分行（以下简称"民生银行"） 签订了《最高额保证合同》，同意为全资子公司湖南达嘉维康医药有 ...

Group 1 - On September 15, Dajia Weikang's stock price fell by 0.59%, with a trading volume of 27.33 million yuan [1] - The financing data on the same day showed a financing purchase amount of 2.91 million yuan and a financing repayment of 4.03 million yuan, resulting in a net financing outflow of 1.13 million yuan [1] - As of September 15, the total balance of margin trading for Dajia Weikang was 88.47 million yuan, accounting for 3.62% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - As of September 10, the number of shareholders for Dajia Weikang was 16,500, an increase of 0.40% from the previous period, while the average circulating shares per person decreased by 0.39% to 8,378 shares [2] - For the first half of 2025, Dajia Weikang achieved an operating income of 2.708 billion yuan, a year-on-year increase of 4.16%, but the net profit attributable to the parent company was only 893,500 yuan, a significant decrease of 97.19% year-on-year [2] Group 3 - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders included the newly entered Noan Multi-Strategy Mixed A fund, holding 939,800 shares [3]

Group 1 - The company, Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd., will participate in the 2025 Hunan Listed Companies Investor Online Collective Reception Day and Semi-Annual Performance Briefing [1][2] - The event will be held online on September 19, 2025, from 14:00 to 17:00, allowing investors to engage through the "Panjing Roadshow" website or its associated platforms [1][2] - Company executives will discuss key topics including the company's performance for the first half of 2024 to 2025, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-061 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。 届时公司高管将在线就公司 2024 年至 2025 半年度业绩、公司治理、发展 战略、经营状况、融资计划、股权激励和可持续发展等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 湖南达嘉维康医药产业股份有限公司董事会 2025 年 9 月 12 日 湖南达嘉维康医药产业股份有限公司 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，湖南达嘉维康医药产业股份有限公司 （以下简称"公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全 景网络有限公司联合举办的"资本聚三湘 楚光耀新程——20 ...

Group 1 - The core point of the article is that Dajia Weikang (301126) reported on September 12 that as of September 10, 2025, the number of shareholders reached 16,456 [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Group 1 - The company has opened multiple 24-hour unmanned pharmacies to enhance operational efficiency and service quality through technology [1] - The initiative aims to provide customers with a more convenient medication purchasing experience [1]